Comerica Bank Grows Stock Holdings in Elanco Animal Health Incorporated $ELAN

Key Points

• Comerica Bank has increased its stake in Elanco Animal Health by 46.4% during the first quarter, resulting in holdings worth approximately $522,000.
• Elanco reported a quarterly earnings per share (EPS) of $0.26, exceeding analysts' expectations of $0.20 and marking a revenue increase of 4.8% year-over-year.
• Several institutional investors have significantly increased their stakes in Elanco, with institutional ownership now standing at approximately 97.48% of the company's stock.

Comerica Bank boosted its holdings in shares of Elanco Animal Health Incorporated (NYSE:ELAN - Free Report) by 46.4% in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 49,680 shares of the company's stock after acquiring an additional 15,754 shares during the period. Comerica Bank's holdings in Elanco Animal Health were worth $522,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the business. Stonepine Capital Management LLC acquired a new position in Elanco Animal Health during the first quarter worth about $105,000. Channing Capital Management LLC grew its holdings in shares of Elanco Animal Health by 11.7% during the first quarter. Channing Capital Management LLC now owns 817,127 shares of the company's stock worth $8,580,000 after buying an additional 85,358 shares in the last quarter. T. Rowe Price Investment Management Inc. grew its holdings in shares of Elanco Animal Health by 1.9% during the first quarter. T. Rowe Price Investment Management Inc. now owns 15,983,391 shares of the company's stock worth $167,826,000 after buying an additional 292,655 shares in the last quarter. Raymond James Financial Inc. grew its holdings in shares of Elanco Animal Health by 9.1% during the first quarter. Raymond James Financial Inc. now owns 951,791 shares of the company's stock worth $9,994,000 after buying an additional 79,668 shares in the last quarter. Finally, Sector Gamma AS grew its holdings in shares of Elanco Animal Health by 72.3% during the first quarter. Sector Gamma AS now owns 477,073 shares of the company's stock worth $5,009,000 after buying an additional 200,166 shares in the last quarter. Institutional investors and hedge funds own 97.48% of the company's stock.

Elanco Animal Health Trading Down 1.4%

Elanco Animal Health stock traded down $0.26 during trading on Friday, reaching $18.52. The company had a trading volume of 5,246,037 shares, compared to its average volume of 10,071,912. Elanco Animal Health Incorporated has a 12-month low of $8.02 and a 12-month high of $19.08. The stock's 50 day moving average price is $16.37 and its two-hundred day moving average price is $13.18. The firm has a market capitalization of $9.20 billion, a price-to-earnings ratio of 21.53, a PEG ratio of 3.49 and a beta of 1.62. The company has a debt-to-equity ratio of 0.61, a quick ratio of 1.40 and a current ratio of 2.60.

Elanco Animal Health (NYSE:ELAN - Get Free Report) last released its earnings results on Thursday, August 7th. The company reported $0.26 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.20 by $0.06. Elanco Animal Health had a net margin of 9.68% and a return on equity of 7.04%. The firm had revenue of $1.24 billion during the quarter, compared to the consensus estimate of $1.19 billion. During the same period in the previous year, the firm earned $0.30 earnings per share. Elanco Animal Health's revenue was up 4.8% compared to the same quarter last year. Elanco Animal Health has set its Q3 2025 guidance at 0.120-0.160 EPS. FY 2025 guidance at 0.850-0.91 EPS. As a group, equities analysts expect that Elanco Animal Health Incorporated will post 0.91 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities research analysts have recently commented on the stock. Leerink Partnrs upgraded shares of Elanco Animal Health from a "hold" rating to a "strong-buy" rating in a report on Thursday, July 17th. Leerink Partners upgraded shares of Elanco Animal Health from a "market perform" rating to an "outperform" rating and set a $18.00 price target for the company in a report on Thursday, July 17th. Piper Sandler lifted their price target on shares of Elanco Animal Health from $12.00 to $18.00 and gave the stock a "neutral" rating in a report on Monday, August 11th. Wall Street Zen upgraded shares of Elanco Animal Health from a "hold" rating to a "buy" rating in a report on Saturday, July 5th. Finally, Zacks Research downgraded shares of Elanco Animal Health from a "strong-buy" rating to a "hold" rating in a report on Wednesday, August 20th. One research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and three have issued a Hold rating to the company. According to MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $17.33.

About Elanco Animal Health

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.